Benzinga | Mar 26, 2021 07:45AM EDT

Raymond James Maintains Outperform on ADMA Biologics, Lowers Price Target to $6

Raymond James analyst Elliot Wilbur maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $7 to $6.